Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Pharmaids Pharmaceuticals Ltd

About the Company - Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 01/03/1989 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L52520TG1989PLC009679 and registration number is 009679. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 3.94 Cr. and Equity Capital is Rs. 10.27 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsUnit 201,, Brigade Rubix, 2nd Floor, 20/14, HMT Factory Main Road, Bengaluru Karnataka 560013compliance@pharmaids.com
http://www.pharmaids.com
Management
NamePosition Held
Mr. Venu Madhava KaparthyExecutive Director
Ms. Mini ManikantanExecutive Director
Mr. Venkata Rao SadhanalaNon Exe.Non Ind.Director
Mr. Mopperthy SudheerIndependent Director
Mr. Methuku NageshIndependent Director
Mr. P N VijayIndependent Director

Pharmaids Pharmaceuticals Ltd. Share Price Update

Share PriceValue
Today₹52.15
Previous Day₹54.89

Basic Stock Data of Pharmaids Pharmaceuticals Ltd

Market Cap 122 Cr.
Current Price 57.0
High / Low79.2/19.7
Stock P/E
Book Value 9.60
Dividend Yield0.00 %
ROCE64.4 %
ROE49.1 %
Face Value 10.0

Data Source: screener.in

Competitors of Pharmaids Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Unichem Laboratories Ltd 3,835 Cr. 545580/272 3420.00 %4.58 %7.05 % 2.00
Biofil Chemicals & Pharmaceuticals Ltd 113 Cr. 69.479.0/35.1171 10.90.00 %4.73 %3.28 % 10.0
Mangalam Drugs and Organics Ltd 195 Cr. 123132/93.8 87.80.00 %6.25 %0.84 % 10.0
Sanofi India Ltd 20,990 Cr. 9,1149,320/5,33036.5 3142.12 %41.4 %30.0 % 10.0
Themis Medicare Ltd 2,228 Cr. 242254/10949.2 39.60.21 %19.7 %17.3 % 1.00
Industry Average66.6 Cr197.6851.34158.860.47%15.33%11.69%6.6

Pharmaids Pharmaceuticals Ltd Quarterly Results

MonthSep 2022Jun 2023Sep 2023
Sales0.000.000.00
Expenses0.541.611.02
Operating Profit-0.54-1.61-1.02
OPM %
Other Income0.000.41-0.26
Interest0.000.000.00
Depreciation0.010.010.01
Profit before tax-0.55-1.21-1.29
Tax %0.00%-7.44%60.47%
Net Profit-0.55-1.30-0.50
EPS in Rs-0.53-0.61-0.23

Pharmaids Pharmaceuticals Ltd Quarterly Chart

Pharmaids Pharmaceuticals Ltd Profit & Loss

MonthMar 2022Mar 2023
Sales3.940.00
Expenses3.819.89
Operating Profit0.13-9.89
OPM %3.30%
Other Income0.020.00
Interest0.000.00
Depreciation0.010.02
Profit before tax0.14-9.91
Tax %0.00%23.71%
Net Profit0.15-7.56
EPS in Rs0.15-3.52
Dividend Payout %0.00%0.00%

Pharmaids Pharmaceuticals Ltd Profit & Loss Yearly Chart

Pharmaids Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-100%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-5140%
Stock Price CAGR
10 Years:34%
5 Years:64%
3 Years:59%
1 Year:99%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:-49%

Pharmaids Pharmaceuticals Ltd Balance Sheet

MonthMar 2022Mar 2023Sep 2023
Equity Capital10.2721.4421.44
Reserves-1.600.67-0.82
Borrowings0.000.000.00
Other Liabilities2.442.480.24
Total Liabilities11.1124.5920.86
Fixed Assets0.030.1110.66
CWIP0.452.002.14
Investments0.003.313.51
Other Assets10.6319.174.55
Total Assets11.1124.5920.86

Pharmaids Pharmaceuticals Ltd Reserves and Borrowings Chart

Pharmaids Pharmaceuticals Ltd Cash Flow

MonthMar 2022Mar 2023
Cash from Operating Activity -0.26-4.02
Cash from Investing Activity 0.47-4.94
Cash from Financing Activity 0.0021.31
Net Cash Flow0.2112.35

Pharmaids Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2022Mar 2023
Debtor Days124.14
Inventory Days90.99-0.00
Days Payable236.18
Cash Conversion Cycle-21.05
Working Capital Days-17.60
ROCE %-64.39%

Pharmaids Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Pharmaids Pharmaceuticals Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters65.84%65.81%65.80%65.65%55.56%35.44%20.70%21.08%16.54%9.95%9.94%9.70%
Public34.16%34.19%34.20%34.35%44.44%64.56%79.30%78.92%83.47%90.05%90.07%90.31%
No. of Shareholders5,2235,8617,1927,3318,3149,6209,4959,1938,1967,7617,4767,393

Pharmaids Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Pharmaids Pharmaceuticals Ltd Shareholders

This stock is not held by any mutual fund

Pharmaids Pharmaceuticals Ltd ROCE Trend

Pharmaids Pharmaceuticals Ltd EPS Trend

Pharmaids Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22
FaceValue10.0010.00
Basic EPS (Rs.)-5.860.14
Diluted EPS (Rs.)-5.860.14
Cash EPS (Rs.)-3.520.15
Book Value[Excl.RevalReserv]/Share (Rs.)10.478.44
Book Value[Incl.RevalReserv]/Share (Rs.)10.478.44
Revenue From Operations / Share (Rs.)0.003.84
PBDIT / Share (Rs.)-4.610.14
PBIT / Share (Rs.)-4.620.13
PBT / Share (Rs.)-4.620.13
Net Profit / Share (Rs.)-3.520.14
NP After MI And SOA / Share (Rs.)-3.520.14
PBDIT Margin (%)0.003.86
PBIT Margin (%)0.003.63
PBT Margin (%)0.003.56
Net Profit Margin (%)0.003.68
NP After MI And SOA Margin (%)0.003.68
Return on Networth / Equity (%)-33.641.67
Return on Capital Employeed (%)-44.091.64
Return On Assets (%)-30.721.30
Current Ratio (X)8.231.09
Quick Ratio (X)8.230.72
Interest Coverage Ratio (X)-2135.7155.63
Interest Coverage Ratio (Post Tax) (X)-1631.2454.05
Enterprise Value (Cr.)34.0112.44
EV / Net Operating Revenue (X)0.003.16
EV / EBITDA (X)-3.4481.73
MarketCap / Net Operating Revenue (X)0.003.26
Price / BV (X)2.081.48
Price / Net Operating Revenue (X)0.003.26
EarningsYield-0.160.01

Pharmaids Pharmaceuticals Ltd Profitability Ratios (%)

Pharmaids Pharmaceuticals Ltd Liquidity Ratios

Pharmaids Pharmaceuticals Ltd Liquidity Ratios (%)

Pharmaids Pharmaceuticals Ltd Interest Coverage Ratios (%)

Pharmaids Pharmaceuticals Ltd Valuation Ratios

Fair Value / Intrinsic Value of Pharmaids Pharmaceuticals Ltd

Fair Value: ₹72.12

The stock is undervalued by 26.52% compared to the current price ₹57

*Investments are subject to market risks

Strength and Weakness of Pharmaids Pharmaceuticals Ltd

StrengthWeakness
  1. The stock has a low average Working Capital Days of -8.80, which is a positive sign.
  2. The stock has a low average Cash Conversion Cycle of -10.53, which is a positive sign.
  1. The stock has a low average ROCE of -32.20%, which may not be favorable.
  2. The company has higher borrowings (0.00) compared to reserves (-0.58), which may suggest financial risk.
  3. The company has not shown consistent growth in sales (1.97) and profit (-4.89).

Should I Buy Pharmaids Pharmaceuticals Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Pharmaids Pharmaceuticals Ltd:
    1. Net Profit Margin: 0.00%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -44.09% (Industry Average ROCE: 24.26%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): -1631.24
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 8.23
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✓ Stock P/E of N/A (Industry average Stock P/E: 20.56)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✗ Total Debt / Equity: N/A
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Pharmaids Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE